Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
Rosa I. Gallagher(George Mason University), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Denise M. Wolf, Laura van ‘t Veer, Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Lamorna Brown Swigart(University of California, San Francisco), Minetta C. Liu(Mayo Clinic), Julia Wulfkuhle(University of California, San Francisco), Douglas Yee(University of Minnesota Medical Center), Nola M. Hylton(University of California, San Francisco), Laura Sit(Memorial Sloan Kettering Cancer Center), Smita Asare(Quantum Leap Healthcare Collaborative), Jean‐Philippe Coppé(University of California, San Francisco), Amrita Basu(University of Calcutta), Ruixiao Lu(Quantum Leap Healthcare Collaborative), Christina Yau(Hospital Authority), Jeffrey B. Matthews(University of California, San Francisco), Mark Jesus M. Magbanua(University of California, San Francisco), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Laura J. Esserman(University of California, San Francisco), Gillian L. Hirst(University of California, San Francisco), Nicholas O’Grady(University of California, San Francisco), Hope S. Rugo(City of Hope), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Michael J. Campbell(University of California, San Francisco), Angela DeMichele(University of Pennsylvania)
Cited by 18
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k